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Abstract  
The number of wholesalers in Japan has been decreasing. This has led to changes for 
wholesalers as they have gone from being dependent on manufacturers to independent. 
Wholesalers focus have changed from local to regional, and in some cases national. As 
consolidations have taken place at the same time as governmental affects, the margins in the 
wholesale industry in Japan have been lowered a lot. Wholesalers are entering into new 
relationships and are trying to find alternative businesses to their core business in order to 
become more efficient and competitive. Alternative business strategies have appeared to 
complement the core business of distribution and warehousing.  
Added value is a way for wholesalers to cope with the low margins. Four big wholesale 
groups who cover around 90 percent of the market have different strategies when 
implementing added values in their operations. They are either focusing on low cost 
operations, or high added value.  The need of efficiency in the Japanese wholesale business is 
crucial today. The already low cost structure in the industry is becoming even lower through 
the use of Information Communication Technology (ICT). ICT makes it possible for 
wholesalers to lower operating costs, shift from speculative to postponement inventory 
management, and increase control.  
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1. Introduction  
This chapter will start to explain the background of the thesis which will lead to the problem 
discussion and the research question that this report aims to answer. In the background we 
will present a description of the Japanese pharmaceutical market in general in order to get an 
understanding of the area. Lastly, we will present delimitations of the report.  
1.1 Background  
Japan is facing problems in the medical area with changing demographics where the 
population is getting older, more chronic diseases occur, a big government debt burden and 
with health care costs increasing at a faster pace than the average income in the country 
(Bloomberg, 2016; MHLW, 2012). The government is now trying to keep a sustainable health 
care system by having costs at a reasonable rate while still providing high quality health care 
(MHLW, 2012).   
In Japan, the government covers large parts of health care costs, which has increased by 20 
percent in the country between 1999 and 2009 (Bloomberg, 2016; MHLW, 2012). By 2012 
the portion of people over 65 years old was 24 percent and is expected to be around 30 
percent in 2025 and 40 percent in 2060 (OECD, 2014). The treatment cost of an elderly 
person is five times as high compared to a non-elderly person (MHLW, n.d.). The share of 
medical treatment by persons 65 years and older have between 2002-2011 increased from 
49.3 percent to 55.6 percent (Alfresa, 2014). The government is continuously working to 
improve the medical health care system due to the aging population as well as a declining 
birth rate (MHLW, 2015).  
Sales in Japan’s pharmaceutical industry have increased. In 2009 Japan accounted for 89.9 
billion dollars in sales compared to 94 billion dollars in 2013, which make Japan the second 
largest pharmaceutical market behind North America (Fool, 2015; JPMA, 2015a). However, 
due to efforts from the Japanese government to decrease drug prices and supporting the use of 
generic drugs, the pharmaceutical market value might decrease (PR Newswire, 2013).   
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1.2 Problem discussion  
As Japan is faced with financial difficulties to take care of high medical care costs, the 
government is using different ways in order to keep the costs reasonable, for example through 
promoting the use of generic drugs and keeping pharmaceutical drug prices down through 
price revisions (MHLW, 2012 ; Alfresa, 2014). One of the most important actors in the 
Japanese pharmaceutical value chain is the wholesalers which have undergone restructures 
due to different external factors (CHEManager, 2013; PR Newswire, 2012).   
The optimal scenario for wholesalers is to have an efficient and quick system in buying and 
selling products, however this can be disrupted by external factors (Nishimura, 2005). 
Manufacturers, medical institutions, and pharmacies are heavily dependent on the wholesalers 
role in the value chain as they act as an intermediate in transactions (JCR, 2011).   
Slater et al. (2008) did a study that looked into the activities of mergers and acquisitions in 
Japanese pharmaceutical companies. They used DiMaggio and Powell’s (1983) concept of 
isomorphism in their theoretical approach and they found that the organizational behavior is 
turning more isomorphic, meaning organizations are becoming more alike. Although their 
study mostly focuses on pharmaceutical manufacturers in Japan, their research approach 
would be as relevant to the pharmaceutical wholesale business. They further find that 
manufacturers make mergers in order to be more competitive and retain the dominance on the 
Japanese pharmaceutical market (Slater et al., 2008). This is noticeable in the wholesale 
market as well. The number of pharmaceutical wholesalers in the supply chain has decreased 
significantly due to consolidations of the wholesalers and today the business mainly consists 
of four big wholesaling groups who control around 90 percent of the market (CHEManager, 
2013). The need of efficiency and ability to offer more than the traditional core business is 
growing even stronger. These changes have made it necessary for wholesalers to reorganize to 
keep up with the changes (Nakamura, 2010).   
Oswald and Boulton (1995) conducted a research about pharmaceutical distribution in the 
U.S. and found that the wholesaler have had to adapt, in their case invest in more technology, 
due to pressures to keep health care costs down. As mentioned in the background part, 
keeping health care costs down is something the Japanese government is working 
continuously with. Therefore, external factors such as this will be of interest to research about 
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when looking at the viewpoint of how pharmaceutical wholesalers in Japan are being 
affected.   
With formal rules, like the Japanese governmental regulations towards the pharmaceutical 
industry, as well as a changing social environment in the nation, there is an opportunity to 
explore the area with a theoretical framework including concepts of these institutional 
changes. Therefore, it is of interest to see if wholesalers behavior can be explained with the 
use of institutional theory.   
To the authors knowledge there is little available research done about how pharmaceutical 
wholesalers in Japan are being affected by external factors per se, that is what this report aim 
to contribute with. As the pharmaceutical business is surrounded by constant change from 
external factors, this thesis further investigates how the pharmaceutical wholesalers in Japan 
are operating and coping with these external changes the industry is exposed to.  
1.3 Research purpose and research question   
The purpose of this research is to give a deeper knowledge in how the wholesaling business in 
Japan works and how the business is being affected by external factors, with help from 
institutional theory. With external factors such as the government with regulations and 
deregulations, the business environment is constantly changing, which have led to the need 
for pharmaceutical wholesalers to adapt to these changes, and this report seek to better 
understand what these acts has had implications for.    
The thesis will be conducted in collaboration with the Danish pharmaceutical company 
Lundbeck Japan K.K. who wants a deeper insight into the Japanese pharmaceutical 
wholesaling industry.  
With the current situation in Japan and for the pharmaceutical wholesalers, the research 
question for this report is as follows:  
"How do external factors affect the Japanese pharmaceutical wholesale industry?"  
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1.4 Delimitations & Limitations  
The pharmaceutical industry has a vast range of actors but we have decided to limit our 
research to the pharmaceutical wholesalers business as this seems to be more of an 
unexplored area. We have decided to look at external factors as those factors affect 
wholesalers and force them to respond in some way. Also, we will concentrate on the use of 
prescription drugs as they represent 93 percent of the sales in the market, and not over-the-
counter drugs as they only represent 7 percent (JFTC, 2014). This report will not investigate 
the external affects caused by natural disasters. The information of pharmaceutical 
wholesalers in Japan is limited to use as most of research related to this area is written in 
Japanese.  
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2. Methodology   
The second chapter will present our methods used in order to conduct the report. We will 
describe our strategy and choice of method and criticism towards our way of research.  
2.1 Research approach  
When compiling a research, the study can be done with a deductive or an inductive approach. 
They can be described as their opposites of each other where an inductive approach looks at 
potential theories after data has been collected, whereas the deductive approach use a theory 
before data is collected and finally test the results towards the used theory (Eisenhardt and 
Graebner, 2007). As mentioned earlier, institutional theory will be the theoretical framework 
of this thesis and it will be used to match the reports results back to the theory and earlier 
research. Therefore, the deductive approach will be used.  
Further, when doing the research, one can approach to do a quantitative or qualitative study, 
or a mixture of them both. Quantitative research is often conducted statistically using data to 
analyze information to reach generalizability (Silverman, 2013). The approach is often 
deductive and gives an objective viewpoint of the reality (Bryman and Bell, 2013). 
Qualitative research puts emphasis on words and not quantification and focus is put on how 
individuals’ personal standpoints relates to the question (Bryman and Bell, 2013). The report 
is going to use a qualitative research method as it is found most useful to answer the report’s 
research question where we want to get a broader picture of the pharmaceutical wholesaling 
business and being able to receive actors opinions about the relevant area. Interviews are 
conducted based on an interview guide with actors in the Japanese pharmaceutical industry. 
The interviews focus, is on how wholesalers work and what difficulties they find with 
changes being made in the market. With interviews from other actors than wholesalers, a 
broader view of the wholesalers will be reached.   
2.2 Research design  
In order to get more information about the Japanese pharmaceutical wholesale business the 
report presents data and research from various articles, newsfeeds and reports. To get another 
point of view, the report contains interviews with key players and relevant people in the 
pharmaceutical market. When conducting a qualitative research, interviews are probably the 
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most common used tool in order to get empirical material (Bryman and Bell, 2013).  Since the 
report is a qualitative research, focus will be emphasized on the interviewees opinion about 
the subject in question.   
As mentioned in the problem discussion, there exist four large pharmaceutical wholesale 
groups in Japan. These are Alfresa Holdings, Medipal Holdings, Toho Holdings, and Suzuken 
Group, which together control around 90 percent of the Japanese pharmaceutical wholesale 
market (CHEManager, 2013). Thanks to contacts from Lundbeck, the report contains 
interviews from two of the biggest wholesaler groups. The report contains interviews from 
Alfresa Holdings and a subsidiary to Alfresa Holdings called Odashima. Interviews were also 
conducted with one of Medipal Holding's subsidiary, Mediceo.  
Further, the report includes an interview with the Swiss pharmaceutical company Ferring 
Pharmaceuticals, and Professor Tsutomu Nakamura, lecturer at Kochi University, whom has 
conducted several reports about the Japanese pharmaceutical market. It further includes an 
interview with consultant Ryuji Deguchi at Lundbeck due to his long experience in the 
pharmaceutical business. Information relating to Toho and Suzuken is collected from 
interviews with Dr. Nakamura, Mr. Deguchi, and Mr. Ooi as well as from secondary data. 
Interviews with Toho and Suzuken were not possible to conduct as they were not available for 
an interview. The interviews contain questions surrounding the research question. Semi-
structured interviews have been conducted, which means that the questions asked have an 
order and is connected to our theme, but there is still room for flexible answers and follow up 
questions (Bryman and Bell, 2013). However, due to different length for the interviews, 
questions have been slightly modified in order to fit the interviewees’ time schedule. All 
interviews were held in Japanese and the interviewees’ answers were directly translated into 
English by consultant Mr. Deguchi from Lundbeck who joined all meetings.   
When conducting this kind of research it is important to take ethical issues into consideration. 
Bryman and Bell (2013) mentions how for example how the researcher should inform 
concerned persons about the research, such as interviewees. Also, it is important to let the 
interviewees participate voluntarily and if they do not want to engage further in the study, 
they can cancel if they wish to. This report has dealt with issues such as these by, before every 
interview, giving a brief presentation of what the thesis is about as well as asking the 
interviewees for permission to record and use the material. Also, Mr. Deguchi has read 
through our report in order to see that what is written is correct.  
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Table 1 below show information about the conducted interviews: 
 
Table 1: Interviews 
2.3 Data collection and analysis  
The report will collect data from both primary and secondary sources. The primary source 
will mainly be through the interviews and various reports from sources such as the Ministry of 
Health, Labour and Welfare, while the secondary data we collect will be through articles, 
 Attendants Position Place Length & date  
Interview 1 
Company: 
Ferring 
Pharmaceuticals  
Takashi Ooi Mr. Ooi: Director, Strategic Distribution 
Planning Department. 
Restaurant in 
Roppongi, Tokyo 
2 hours 
 
2016-04-12 
 
Interview 2 
Kochi 
University 
Tsutomu 
Nakamura 
Dr. Nakamura: Ph.D.  
Lecturer at Kochi University 
Kochi University, 
Kochi 
2 hours 
 
2016-04-13 
 
Interview 3 
Company: 
Alfresa 
Holdings 
Toshikazu 
Urakabe and 
Koichi 
Shimada 
(Alfresa 
Pharma 
Corporation) 
Mr. Urakabe: Manager, Group 
Administration & Affiliate Control 
Department 
 
Mr. Shimada: Executive Vice President 
Corporate Planning, Product Strategy 
Alfresa 
headquarters, Tokyo 
3 hours 
 
2016-04-19 
 
Interview 4 
Company: 
Mediceo 
(Medipal 
Holdings)  
Shoji Nagao 
and Takashi 
Ooi 
Mr. Nagao: Manager, Purchase Strategy 
Group 
Medipal 
headquarters, Tokyo 
1 hour 
 
2016-04-26 
 
Interview 5 
Company: 
Lundbeck 
Japan 
Ryuji Deguchi Consultant Lundbeck office, 
Tokyo 
1 hour 
 
2016-05-09 
 
Interview 6 
Company: 
Odashima 
(Alfresa 
Holdings) 
Kazunari 
Oikawa, Jin 
Onodera, 
Toshikazu 
Urakabe and 
Koichi 
Shimada 
Mr. Oikawa: Corporate Officer, Business 
Planning 
 
Mr. Onodera: Corporate Officer, Head of 
Administration  
Odashima 
headquarters, 
Hanamaki 
2 hours 
 
2016-05-18 
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journals, newsfeeds and books connected to our relevant area. Collection of both secondary 
sources combined with performed interviews has made it able to present current information 
about the pharmaceutical wholesaling industry, as well with the viewpoint of the interviewees 
who are well-informed and can add extra insight to the empirical findings. When analyzing 
the data, qualitative research differs from quantitative research in a sense that the qualitative 
approach digs deeper into the understanding of the data (Sandelowski, 2000). With the 
deductive approach, this report will connect the theoretical framework to the empirical 
findings and earlier research on the area to see if it can be related by finding similarities or 
differences.  
2.4 Method criticism       
As the method of choice is of qualitative research, the report will access deeper information 
about the pharmaceutical wholesale industry with the interviews and descriptive empiricism. 
However, due to the limited time, the number of actors included in the report is limited. With 
few actors interviewed, it is difficult to get a complete representation of how the industry is 
affected. This problem is not uncommon for qualitative studies and it is difficult to transfer 
the results to other areas (Bryman and Bell, 2013). The two big wholesaler groups 
interviewed cover around 50 percent of the market, though, individuals are represented from 
the wholesalers and therefore it is only their point of view we are receiving. Further, due to 
time restrictions in interviews the respondent’s answers will sometimes be summarized in 
English, making it impossible for the report’s authors to know all words the respondents said 
which means that details might be missed. It is therefore important for the readers to 
reconsider this when reading this report, and for the authors when analyzing the data. The 
report does however still believe that the qualitative approach is the best suited methodology 
for the thesis as it can back up findings with thorough market research and that interviewees 
have strong experience and positions to tell detailed information about the market situation.  
2.5 Reliability and validity 
The meaning of reliability is if the study would get the same outcome if it was conducted in 
the same way again (Bryman and Bell, 2013). The report is reliable as it has used a lot of 
descriptive information in the empirical research, which can be used in other reports. 
However, as the pharmaceutical industry is constantly changing and especially in Japan where 
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the demographic situation is undergoing a significant change, results could differ in future 
reports. The report asks how wholesalers are affected in the moment and thus future changes 
in the industry will certainly lead to other explanations and solutions which would affect the 
reliability. Validity is about whether the research can answer the concept it was supposed to 
answer (Bagozzi et al., 1991). To ensure a greater validity, interviews with key actors have 
been conducted within the research area together thorough collecting and presentation from 
secondary sources explaining the pharmaceutical wholesaling business in Japan to create a 
clear, yet detailed overview of the area and how external factors change it.  
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3. Theoretical framework  
This chapter will approach the theoretical framework that will be used for this thesis. The 
chapter will start by presenting the essentials and explaining institutional theory, as this 
theory will be the framework for discussion in the analysis of the thesis. After the explanation 
of chosen parts from the institutional theory, critique against the theory will be presented and 
then address how these parts of the theory are suitable for the research before presenting a 
brief summary. Finally, the chapter will show earlier research done in the distribution area.  
3.1 Institutional theory  
The word institution can be related to stability and structure (Scott, 2008). Institutional theory 
doubts that organizations act rationally, but instead adapts to its surroundings (Powell and 
DiMaggio, 1991). However, institutions do change both under internal and external factors. 
External factors could be political, social or economic whereas internal factors for example 
could be to not deliver expected performance within the institution (Scott, 2008). When it 
comes to new institutional economics, one of the pioneers in the area, Douglass North, 
mentioned that “Institutions are the rules of the game in a society or, more formally, are 
humanly devised constraints that shape human interaction” (North, 1990:3). He makes a clear 
distinction of the difference between institutions and organizations. As mentioned, he 
describes that institutions are the rules in a game. Organizations on the other hand, are 
described as the players in the game. The organizations are groups of individual persons and 
together in forms of a group they try to achieve a certain goal. He further brings up that 
history is essential as institutions learn from what has happened in the past and that decisions 
in the future are formed by events in the past. The cultural aspects also play a large role in the 
way how institutions develop as cultural characteristics has a strong tendency to survive as 
these are not immediately affected by changes in formal rules such as laws (North, 1990).  
The reason institutions exist is because of uncertainty between humans and this uncertainty 
exist due to the complexity in problems that can emerge. Another complexity is the 
surrounding environment where uncertainty in form of incomplete information can arise. It is 
here from that rules and procedures gets created to lessen the uncertainty. Institutional 
frameworks, that is the system of organizational forms, laws and norms, exist in all 
economies. These institutional frameworks provide opportunities for organizations and it is 
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political and economic entrepreneurs who wants to maximize profitability in the short run that 
makes up for changes in institutions (North, 1990).  
One of the branches in institutional theory is the approach of new institutionalism, which one 
could say was introduced in 1977 after John Meyer and Brian Rowan’s published paper 
“Institutionalized Organisations: Formal Structure as Myth and Ceremony” (Powell and 
DiMaggio, 1990). Meyer and Rowan (1977) states in their paper that institutionalized 
policies, products or techniques can be considered as “myths” and organizations adapt and 
implement these to gain legitimacy, stability and to survive. Further, they describe that 
organizations integrate factors that are considered externally legitimate, and success for an 
organization is not depended on efficiency or the control of its activities. By becoming alike 
its environment, the organization receive its legitimacy and can survive.  
3.1.1 Isomorphism and Organizational fields  
A major concept in new institutionalism is institutional isomorphism. This is an idea that 
derives from that organizations are becoming more alike each other. Bureaucracy is a frequent 
organization form according to DiMaggio and Powell (1983) and bureaucratization and 
different kinds of organization changes takes place because of the strive towards 
homogeneity, or institutional isomorphism. However, this does not automatically make the 
organizations more efficient. Homogenization appears from network of so called 
organizational fields. Organizational fields can be described as a field where organizations 
within the same area operate. For example, the field could be a specific industry with 
manufacturers, distributors, competitors, regulatory organizations etcetera. When the 
organizational field has settled and has been more established, strong forces towards making 
the organizations more identical is created in the field (DiMaggio and Powell, 1983).   
As mentioned before organizations do change. They change the way they are operating and 
can change their target goals. Also in the organizational field, new players can enter but to 
enter the market the newer entrants use isomorphism and adapt to the standards and 
procedures that already exist in the field. However, it is worth to notice that in a long term, 
when rational decisions are being made by the organizations they create a surrounding that 
makes it more difficult to change the organization in the future. If just one single organization 
has a strategy that is considered rational, it might not be a good strategy if implemented by 
several organizations. But since organizations in the organizational field get more 
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homogenized, there exist a higher probability that other organizations adapt to each other’s 
strategies. Therefore, it seems like organizations continually change, but after some time the 
field gets less diversified (DiMaggio and Powell, 1983).   
DiMaggio and Powell (1983) describes three different kinds of isomorphism; Coercive, 
mimetic and normative. Coercive isomorphism mostly reflects political force. Both formal and 
informal demands are being applied on organizations by other organizations. This pressure 
can for example arise from governmental decisions, such as rules or laws, that then 
organizations in the field are more or less forced to apply in the field. It is often these bigger 
institutions that are the ones who set the rules in the field and the other smaller organizations 
are the ones who have to change, and therefore making the organizations more homogeneous. 
The more dependency between organizations, the more alike each other they will become as a 
result from isomorphic change as coercive forces enter into organizations relationships 
(Pfeffer and Salancik, 1978; Thompson, 1967 as cited by DiMaggio and Powell, 1983). 
DiMaggio and Powell (1983) refer to Williamson (1979):  
…exchanges are characterized by transaction-specific investments in both knowledge 
and equipment. Once an organization chooses a specific supplier or distributor for 
particular parts or services, the supplier or distributor develops expertise in the 
performance of the task as well as idiosyncratic knowledge about the exchange 
relationship. The organization comes to rely on the supplier or distributor and such 
transaction-specific investments give the supplier or distributor considerable advantages 
in any subsequent competition with other suppliers or distributors. (DiMaggio and 
Powell, 1983:154).  
The second kind of isomorphism is mimetic. This comes from the uncertainty that can appear 
from the organizations. For example, if a company feels that they use technology that is 
difficult to understand, have unclear goals or if the environment is uncertain the company can 
seek to imitate another company. However, the company or organization that is being imitated 
does not have to be aware that they are being imitated. Uncertainty is therefore another reason 
for strengthen imitation between organizations. The third and final isomorphism is the 
normative. Normative isomorphism derives from professionalization and DiMaggio and 
Powell (1983) present that professions too are exposed to mimetic and coercive forces, just 
like organizations. Professionals at organizations can act similar to each other due to factors 
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such as related education and the network created by the workers and knowledge can then be 
distributed among the professionals in the same area.  
It can be said that these three kinds of isomorphism lead to identical organizations and though 
it does not mean that the organizations necessarily become more efficient, their similarity can 
be seen as a reward. This is because it will be easier for the organizations to connect with each 
other and thus be seen as more legitimate. Status competition is also something that pushes 
organizational fields that has professional labour towards isomorphism as organizations want 
to assure that they can be as good as competitive organizations (DiMaggio and Powell, 
1983).  
3.1.2 Criticism towards institutional theory and isomorphism  
Institutional theory has existed and been developed for a long time and although the theory is 
widespread, it has received critique. Hasselbladh and Kallinikos (2000) aimed criticism 
towards the new institutional theory claiming that it can be both too idealistic and too wide 
when doing research that is empirical and that it should go more into detail as it now mostly 
shows an overview.    
Regarding the concept of isomorphism, Beckert (2010) thinks that this approach is just 
focused on one side as it leaves out alternative institutional approaches and “does not do 
justice to actual social change because it overlooks the role played by divergent institutional 
development” (Beckert, 2010: 150). He mentions that the new institutionalism leans towards 
only homogenization through the idea of isomorphism and not divergence, and he means that 
DiMaggio and Powell’s factors for isomorphism can also lead to divergent change. Factors 
such as strong external forces or competitiveness in similar markets are supportive for 
institutional homogeneity while factors such as how countries differ from each other and 
demands in a certain industry are supportive for divergence.   
However, it is still believed that the theory is relevant for this research since the components 
of the organizational field fits well with what has been brought up in the theory chapter, but 
these opinions of institutional theory will be taken into reconsideration when analyzing the 
thesis.   
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3.1.3 Implications for the thesis  
The pharmaceutical industry, and the wholesale system, is covered by regulations. As the 
pharmaceutical sector is under constant change this report will look into how institutional 
theory implements in this area. While focusing on wholesalers, which have been decreasing in 
numbers as well they are trying to keep their margins up this theory is relevant for the 
qualitative research.   
As the thesis will see how external factors affect the wholesalers, institutional theory brings 
up interesting areas in how organizations change through its environment when it comes to 
factors such as social and political, which are of well significance. For example, with the 
framework the thesis can later discuss if DiMaggio and Powell's (1983) concept of 
isomorphism is adaptable to the report’s research question.  
3.1.4 Summary of institutional theory 
To summarize the used theoretical framework, these concepts from institutional theory have 
showed that institutional change can come from external factors such as social, political and 
economic (Scott, 2008). North (1990) for example, mentioned how organizations strive 
towards a common goal and how uncertainty arises from complex problems and to lessen the 
uncertainty, rules gets created. Further, Meyer and Rowan (1977) described how 
organizations adapt to its surrounding to receive legitimacy in order to survive. DiMaggio and 
Powell (1983) presented how organizations in an organizational field become more alike each 
other with isomorphic behaviour, something that can be explained through three mechanisms:  
Coercive  
 Bigger organizations pressure smaller ones. Mostly political forces. 
Mimetic  
 Organizations imitating other organizations due to uncertainties. 
Normative  
 Isomorphic behaviour through professions.  
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3.2 Earlier research  
3.2.1 Developing distribution and expanding areas 
Rawwas et al. (2008) did a study on how new collaborations between wholesalers in the 
Osaka and Hyogo prefectures in Japan affected their performance. The authors mention that 
the optimal collaboration is to have a distribution system where wholesalers delivers the right 
product, does it on time, keep inventory low and develop customer service functions. By 
entering into new relationships, wholesalers competitive position becomes stronger. In order 
to reach this optimal collaboration, it is important for the trading partners to share information 
between each other. In their article, Rawwas et al. (2008) mentioned several concepts when 
conducting building their hypotheses such as traditional marketing theory, supply chain 
management ideas and transaction cost theory. They used a quantitative approach and the 
research included a wide range of wholesalers in industries such as motor vehicles, food, 
electronics and drugs. They found that it is important for the wholesaler that the suppliers 
bring well-known brands for driving the wholesalers inventory as the Japanese customers 
preferred domestic brands and were keen to use quality products, as it offered customers 
belief and minimized the risk associated with the product. Further on, the study found that the 
use of just-in-time, to deliver the product when it’s needed, and the use of additional logistics 
was the most important factor for the wholesalers’ efficiency. In order to increase 
performance, wholesalers have to add value to their business and expand their business to 
provide services not only in distribution.  
Nakamura (2010) researched about how regional differences exist in business development 
between Japan, the US, and Europe. He concludes that in order for wholesalers survival, they 
need to deliver health care services and business solutions outside their basic wholesale 
functions. He further adds how distribution are more tailored to each specific product, as 
faster deliveries and more advanced information are being requested by customers.  
3.2.2 Consolidations, the use of ICT and innovation strategies 
Oswald and Boulton (1995) found that consolidations in the pharmaceutical industry have 
been done on all levels due to lower profitability. They did a case study about the 
pharmaceutical distribution in the U.S. and found that strategy ideas about cost, differentiation 
and niche from Michael Porter were successfully implemented by a couple actors in the 
16 
 
distribution industry. They presented in their conclusion how market pressures to keep health 
care costs down have made wholesalers invest in technology. The U.S. pharmaceutical 
wholesalers also differentiate from each other and their role in the distribution chain is 
becoming stronger as a result from increased technology usage and providing more service to 
their customers. Further, they mention that wholesalers have witnessed lower margins and 
therefore the wholesalers have to compensate by increasing sales volume in order to be able to 
afford investments in large distribution centers. Distributors are therefore looking after 
products that can generate higher margins. Lastly, the authors discuss that wholesaler who 
does not adapt and use innovative strategies will probably not survive in the future.   
Maruyama (2004) researched about what changes that affected Japanese distribution channels 
when it comes to both structure and strategy by mostly using data from the Japanese Ministry 
of Economy, Trade and Industry’s Census of Commerce report. He mentions that the data 
from the Census of Commerce report has showed reduced steps in distribution channels and 
distribution restructuration due to IT innovations. Due to factors such as product 
diversification and an uncertainty in demand, there has been a change in the business. The 
distribution has gone from speculative to a postponement inventory approach. Because of this 
new approach, focus has been put on improving the efficiency in the supply chain by 
changing logistics and inventory management. With the reorganizations in the distribution 
system, Maruyama (2004) discusses three ways where the industry is heading. Firstly, as 
retail sales have gone from small-scale specialty stores towards the bigger mass retailers, the 
traditional vertical distribution is no longer in use because of the consolidations being done on 
a horizontal level for both retailers and wholesalers. The bigger wholesalers are doing 
mergers and acquisitions with local wholesalers making the steps in the vertical distribution 
chain smaller. Secondly, there has been a move in strategies from production-driven to 
consumer-driven distribution which for example can be seen in the inventory management 
going from a speculative to a postponement approach. Wholesalers are also acting more as 
buying agents for customers and retailers rather than being sales agents for the manufacturers. 
Thirdly, with the increased use of information technology, the distribution is becoming more 
integrated when it comes to decision making as information is being shared more. Finally, 
Maruyama (2004) argues that with a direction moved to more integrated distribution channels, 
he find two kinds of effects which he call linkage and “blockade” effects. The linkage effect 
means the positive outcomes like increased efficiency in the distribution chain, whereas 
“blockade” effects points out the negative outcomes such as exclusive relationships as a result 
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of consolidation of the actors in the supply chain which would decrease competition in the 
distribution business.   
Hashimoto (2000) did case studies on the Japanese distribution system and analyzed how the 
development of information technologies affects spatial structure of organizations. He found 
out that development of ICT will lead to a smaller and more concentrated wholesale market 
characterized by a few leading wholesalers. Further, Hashimoto (2002) did a study on how 
information technology affects consumer goods distribution found out that the use of 
information technology has reduced costs in different ways. First he discusses how it has 
prevented a reduced loading efficiency which has been a problem with the frequent small 
scale deliveries as it contributes to a reduced ordering time and increases the dimensional 
capacity for which deliveries are possible within a fixed lead time. He further discusses how 
information technology has reduced the stock indirectly through integration and 
automatization of distribution centers and how forecasts have been improved. In another 
research, Hashimoto (2003) further discusses the ITs affect on distribution system with focus 
on economic geography. He discuss how the automatization of work tasks in wholesalers and 
the integration will mean that distribution centers are going to be located in suburbs due to 
traffic conditions than in urban areas, separated from information functions that will be placed 
in big cities. Further, he discuss how only focusing on cost reduction has reached its limit. 
Hashimoto (2003) also mentions that wholesalers who do not take IT in use will face 
problems as many of them will not be able to survive in the business. The bigger wholesalers 
will however be able to take advantage of economies of scale with their large distribution 
centers they are building which will make the situation even tougher for smaller firms.   
3.2.3 Summary of earlier research  
This section of earlier research showcased some articles about distribution relevant for this 
report. The increased use of technology in the distribution industry seems to be of utmost 
importance as this is mentioned by almost all authors in the presented earlier research. 
Further, Hashimoto (2002) found that with information technology, distribution centers have 
been able to keep their stock down and forecasting has been improving which is similar to 
what Maruyama (2004) found, that there has been an inventory management shift going from 
a speculative order approach to a postponement approach. Rawwas et al. (2008) also 
mentioned that it is optimal to have a low inventory stock. According to Oswald and Boulton 
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(1995), wholesalers have to create innovative strategies to survive and similarly, Nakamura 
(2010) found that in order to survive wholesalers have to look for business solutions beyond 
their core business.  
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4. Empirical findings  
This chapter is intended to give an explanation of how the pharmaceutical wholesaling 
business has developed and what parts it is built upon. It will present how wholesalers work, 
their functions, what external factors affect them and how they have responded to these. The 
empirical findings will be presented with descriptive facts as well as interviews into the text.  
4.1 The role and functions of wholesalers 
The wholesalers four main functions are (JPWA, 2010; JPWA, 2015);  
1. Delivery function; handles distribution of pharmaceutical products and returned 
pharmaceuticals.  
2. Inventory function; Handles orders and prepares for delivery. 
3. Information functions; collects and provides information about pharmaceutical 
products, and marketing for medical prescribers.  
4. Financial function; Price negotiations and debt management.  
 
Figure 1:Wholesalers main functions. (JPWA, 2015). 
Wholesalers buy drugs from manufacturers and sell it on to medical institutions and 
pharmacies (JPWA, 2015). The wholesalers goal is to offer stable supply of pharmaceutical 
drugs in order to meet the demand from the approximately 230 000 hospitals, clinics and 
dispensing pharmacies in Japan (JPWA, 2010). Wholesalers receive pharmaceutical drugs 
from manufacturers to their distribution centers, Mr. Urakabe says. Big wholesalers have 
more distribution centers than smaller ones. Alfresa have 22, while small wholesalers only 
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have one. The location of distribution centers depend on the number and density of people, 
and infrastructure. The drugs can either go directly from the distribution center to pharmacies 
or medical institutions, or they will be delivered through branch offices, he adds. Mr. Oikawa 
adds an example of how Odashima covers five prefectures through 19 different branch 
offices, with drugs stored in the distribution center in Hanamaki, Iwate prefecture. When 
orders are received, drugs are delivered to branch offices during night time. Local branch 
offices then distribute the drugs to pharmacies or medical institutions, Mr. Oikawa says.   
The Japanese pharmaceutical wholesale system is multilayered with many branch offices 
spread out around Japan (Nakamura, 2013). Alfresa have 200 different branch offices spread 
out around Japan, Mr Urakabe says. The multilayered Japanese wholesale system is affected 
by the retail market whose tendency in Japan is to have many small stores (Maruyama, 2004). 
The branch offices are located close to each other with focus on small areas. Branch offices 
are handling low volume orders and are able to respond to orders quickly as they are located 
close to the delivery points. (Nakamura, 2013). Different from wholesalers in America and 
Europe is the Japanese wholesalers special functions when it comes to information. Not only 
do they handle information about the pharmaceuticals, they also help physicians when 
choosing drugs (JPWA, 2010).  
In Japan, the wholesalers present an exclusive function in the form of Marketing Specialists 
(MSs). With around 20,000 MSs operating in Japan, they work with promoting and sales of 
products to prescribing physicians and pharmacists. The MSs keep a very close contact with 
these actors as they make around 5.3 million calls to them every year (Suzuken, 2010).   
The characteristics of MSs have been their effort for sales promotion and deliveries. Measures 
have been taken to increase efficiency and automatization of different tasks. For example MSs 
have increased automatization for payment operations, and the introduction of delivery 
specialists who is taking care of distribution, something that have narrowed the focus area for 
MSs, Mr. Deguchi and Mr. Nagao says. MSs are today taking care of inventory and 
information functions in wholesalers operations (JPWA, 2010; MHLW, 2007).  
The information function for MSs is very important. For example, in Japan there is around 90 
000 clinics present. Medical Representatives (MRs) finds it difficult to cover all clinics, 
especially all small ones, leaving the providing of information in the hands of MSs. MSs who 
cover those small clinics distribute basic information about the products, and if more 
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information is required by the clinic, MSs then transfer that request to MRs who then go and 
visit the clinic to provide more detailed information, Mr. Nagao says. He adds that MSs deal 
with tens of thousands of different drugs, while MRs deal with hundreds at most. This system 
is efficient with the big force of MSs reaching the big audience, and if more specific 
information about a drug is requested, MRs will cover up with deeper knowledge.   
Mr. Nagao says that the need for MSs is crucial to cover the Japanese market, especially in 
small clinics where MSs presence is higher than MRs. Mr. Oikawa adds that this is often the 
case in less populated areas like isolated islands where many MSs have worked for many 
years and have good relations with physicians and pharmacies.    
In these areas, MSs have a bigger role than they have in big cities. The lack of MRs present 
on those places make the role of MSs bigger. In return, higher commissions are being paid by 
manufacturers, and therefore wholesalers receive a higher relative profit in isolated areas 
relative to urban areas, according to Dr. Nakamura. Mr. Deguchi says that it is very cost 
efficient for pharmaceutical companies, it is very favorable for wholesalers to have MSs 
present in such locations. Every year, Suzuken's number of MSs they add on customers 
increase (Suzuken, 2014).  
4.2 Evolution of pharmaceutical wholesaling in Japan   
Wholesalers as part of the distribution system have always been very important for the 
pharmaceutical industry in Japan. 98 percent of sales from a pharmaceutical manufacturer in 
Japan goes through a wholesaler. A big reason for this is the lack of space in pharmacies 
operating in Japan, therefore just-in-time deliveries become crucial from wholesalers who are 
able to keep the necessary stock for pharmacies (PharmAsia, 2013). Over the years, the 
Japanese pharmaceutical wholesalers have experienced changes due to restructures in the 
pharmaceutical industry. Changes in consumer needs, the retail industry, and the evolution of 
ICT have led to consolidations and diversifications (JPWA, 2015; Reed Maurer, 2011; 
PharmAsia, 2013). Dr. Nakamura emphasizes the clear characteristic in the Japanese 
distribution system to go through wholesalers and Mr. Urakabe adds that the cost is higher for 
pharmaceutical manufacturers to distribute products by themselves than through a 
wholesaler.   
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As wholesalers act as the intermediate in drug deliveries, their core business, which is 
distribution, is dependent on the drug price margin which is the difference between the selling 
and buying price for wholesalers. Pharmaceutical manufacturers want to keep high prices, 
while medical institutions and pharmacies want to buy cheap from wholesalers in order to 
maximize their profits. As the margins are getting lower through different external factors, the 
wholesalers’ business strategies and models have been changing. Governmental changes in 
1990s forced wholesalers to reorganizations in order to remain competitive on a market where 
it is getting more difficult for every year to survive (JCR, 2011).   
Before consolidations took place, each wholesaler was tied to a manufacturer as a group 
company and their product portfolio were specialized according to the manufacturer’s 
production (JCR, 2011). After years of consolidations, the big four wholesalers accumulated 
power, as their power on the market today can tell. The majority of Japanese pharmaceutical 
wholesalers are in some way connected to these big four wholesalers. (CHEManager, 2013; 
JPWA, 2010; PharmAsia, 2013; Reed Maurer, 2013a)    
The big four all have similar product portfolios and cover almost the whole market, therefore 
the competition relating to products focus on low prices. The reorganizations have made it 
difficult for wholesalers to survive by only focusing on their core business due to low 
margins, therefore some wholesalers have expanded their operations to include both 
manufacturing and dispensing pharmacies (JCR, 2011).    
4.3 Mergers and acquisitions, a corner stone in the evolution of pharmaceutical 
wholesalers    
The restructures wholesalers have done, have mainly been through M&As which were 
necessary due to deregulations made (JETRO, 2005). These M&As led to fewer numbers of 
wholesalers, lower costs, and economies of scale which made the wholesalers more 
competitive and efficient, but also to a more diversified business model (JETRO, 2005; Reed 
Maurer, 2011; Slater et. al., 2008).   
In 1970 there were more than 1200 wholesalers who in some way were connected with big 
pharmaceutical manufacturers like Takeda, Shionogi, Mitsubishi Tanabe, and Daiichi 
(PharmAsia, 2013). Wholesalers were dependent on manufacturers as they wanted the right to 
sell the manufacturers drugs in the local area they covered (PharmAsia, 2013; Reed Maurer, 
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2011). Characteristics of the wholesale business at that time were their local presence with 
focus on Japan's 47 different prefectures where each manufacturer usually had at least two 
different wholesalers (OECD, 2006; PharmAsia, 2013). Except from these two wholesalers 
within each prefecture, it was common for manufacturers to have some extra wholesalers and 
in total the number often added up to 150-200 different wholesalers for a single manufacturer 
to cover the Japanese market (PharmAsia, 2013; Reed Maurer, 2011).   
Wholesalers tried to acquire distribution rights from pharmaceutical manufacturers. They tried 
to find manufacturers with a wide product range and many MRs. The MRs tried to promote 
drugs to doctors and medical institutions, which made wholesalers visible for many potential 
buyers (Reed Maurer, 2011).    
Consolidations increased the area covered by wholesalers, which have made wholesalers 
focus more on a regional level, and as in the case of the big four groups, the focus is on a 
national level (PharmaAsia, 2013; Reed Maurer, 2011). By covering a bigger area, 
pharmaceutical manufacturers became more interested, and that led to a shift in focus towards 
customers instead of manufacturers (Reed Maurer, 2011; PharmAsia, 2013). Wholesalers 
bargaining position towards manufacturers have increased (JETRO, 2005). In 1995 those 
1200 wholesalers had consolidated and become 251, and by 2013 this number was just over 
hundred wholesalers covering regional and local areas with the big four groups covering the 
whole nation with help through branch offices and relation to strong local wholesalers (Reed 
Maurer, 2013a; PharmAsia, 2013). Today, the big four wholesalers have a similar product 
portfolio, what differs depends on how wholesalers relationship with foreign pharmaceutical 
manufacturers is, Mr. Ooi says.   
The big four wholesale group’s goal is to cover the whole of Japan, from Hokkaido to 
Okinawa, though some local wholesalers in specific areas are very strong, and will not be 
included in an M&A, therefore the big four are dependent on local independent wholesalers to 
cover the country Mr. Deguchi says. Mr. Urakabe says how Alfresa's mid-term goal between 
2002-2012 was, through M&As, to expand their business area with the goal to cover the 
whole Japanese market through group wholesalers.    
Many small and mid-sized wholesalers merged with bigger wholesalers which has made the 
wholesale market in Japan very concentrated (Nakamura, 2002). The consolidations have 
eased the burden for pharmaceutical companies as the number of wholesalers needed to cover 
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the market have been reduced (PharmaAsia, 2013). Wholesalers receive commissions from 
pharmaceutical manufacturers based on different volume of sales. In addition to these 
commissions, as incentives for wholesalers to sell as much as possible, there are performance 
fees. These fees are paid when wholesalers make manufacturers a favor. For example, the 
reduce in number of wholesalers meant that distribution centers decreased and the burden for 
manufacturers also decreased as they did not need to handle with the same amount of 
distribution centers anymore, therefore a performance fee to wholesalers was paid. Other 
ways is when wholesalers exceed the pre-agreed levels of sales amount included in the 
contract, wholesalers will receive a performance fee for this effort from the manufacturer, or 
if they can reduce the number of invoice days, the performance fee will be paid. There are 
different measures by manufacturers to give wholesalers the extra incentive to act in their 
favor by providing this performance fee, Mr. Ooi says.  
According to Dr. Nakamura, Mediceo merged together with Paltac, becoming Medipal, in 
order to take advantage of Paltac's widespread and established distribution network. By doing 
that, Mediceo's distribution costs were lowered. The M&As also increased their operating size 
and led to the acquisition of improved human resources, Mr. Nagao says. The bigger size of 
the wholesaler through M&As made them able to spend more money on a new distribution 
system and distribution centers which contributed to the reduce of the need of branch offices 
as they could be bypassed by the new distribution system, and therefore Mediceo could 
reduce costs.  
4.4 The need of complementary wholesalers  
The big four cover almost the whole Japanese market together, but they do not necessarily 
own all parts of their distribution system. Mr. Ooi says, when Ferring Pharmaceuticals chose 
Alfresa as the wholesaler to cover the Japanese market, the health ministry in Japan 
recommended Ferring to look for complementary wholesalers as Alfresa do not cover the 
whole Japanese market.  
Mr. Ooi mentions that Ferring Pharmaceuticals deals with 14 different wholesalers. The 
reason is that the strength of local wholesalers is higher than the big four due long lasting 
relationships with medical institutions and pharmacies. In selected areas MSs have worked for 
local wholesalers for many years and built up relations with prescribing pharmacies and 
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physicians which make it difficult for the big four to break through. He adds that even though 
the big four have a lot of national power, the need of local wholesalers is still there.  
As Alfresa lacked a branch office in northern part of Japan, Hokkaido, Ferring decided to start 
cooperation together with the local wholesaler Moroo after recommendations from Alfresa. 
Moroo did not have a financial relationship with Alfresa, though they had historical relation 
and cooperated in the marketing function. Alfresa did not cover the Kyushu area and Shikoku 
area either, due to strong local wholesalers covering those areas, which made Ferring start 
with direct sells in those areas. Though Mr. Ooi emphasizes that direct sells only was a short 
term solution as Ferring see the wholesalers as an important actor in the Japanese 
pharmaceutical market, and therefore they decided to start business with Medipal and then 
further expanded their relations with other wholesalers in order to cover the whole Japanese 
market.  
4.5 The governmental impact 
4.5.1 Health expenditure  
The health care expenditures in Japan are steadily increasing (MHLW, n.d.). The country is 
the third highest spender in the world when it comes to health care, and the main part is 
covered by the state. In 2014, health care costs as part of governmental expenditures was 20.3 
percent in Japan (World Bank, 2016).   
In 2013, 56 percent of total social security expenditures were covered by the premiums. The 
rest of the gap needs to be covered by the government. As a response to the gap, reforms by 
the government are ongoing (Deloitte, 2015). For example through the consumption tax rate 
that was raised from 5 percent to 8 percent in 2014 (Trading Economics, 2016). In 2017, a 
further increase to 10 percent is planned (International Business Publications, 2016), which 
together with more frequent price revisions, starting from this year, have brought uncertainties 
to the industry (R&I, 2015).   
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Figure 2: The gap between social security expenditure and expected national health care 
expenditures. (Deloitte, 2015). 
In an effort to lower health care expenditures, emphasis has been put on NHI reimbursement 
price revision and promotion of generic drugs (Bloomberg, 2016; IHS, 2015). The increased 
usage of generic drugs and price revision, affects wholesalers’ sales and profits. In the fiscal 
year of March 2015, where it ends, the biggest four wholesaler groups had an average 
operating profit of 0.82 percent and the market growth decreased due to increased 
consumption tax, the price revision of drugs and reduced sales of branded drugs. The big four 
wholesaler groups operating profits decreased 21.2 percent compared to the year before. The 
reason behind this drop is the generic drugs increase in share at the expense of long-listed 
drugs (IFPW, 2015b). Mr. Urakabe says that the financial conditions is being heavily affected 
by the government's initiative and adds that in order to survive one of the responds from 
Alfresa is trying to expand their business to foreign countries as the tendency of lower 
margins is likely to continue.   
Dr. Nakamura mentions that the government tries to reduce the cost of the public health care, 
but they are not taking the wholesalers margins into consideration. Wholesalers gross profit 
margins will continue to decrease, though the expected drop in profit is not as big as 
wholesalers have separated the role of MSs who more efficient perform their information and 
marketing function, as investments in logistics to specialize in distribution of drugs, in 
combination with income sources weighted towards other business segments, partly weighs 
up the lower margins (R&I, 2015).  
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4.5.2 NHI Reimbursement Price Revision   
In Japan, the government decides the end price of prescription drugs included in the price 
revision scheme (Pacific Bridge medical, 2015). Mr. Oikawa mentioned that the anti-
monopoly law is not adaptable to the pharmaceutical industry as the price revision functions 
in a similar way. The end price is decided through the price revision that from 2016 takes 
place every year, instead of every second year, as it has been done until now (Pacific Bridge 
Medical, 2015). The drug prices, decided by NHI reimbursement price revision, follow actual 
market prices and the goal of the revision is to reflect the actual market price and lower the 
health care costs in Japan (Suzuken, 2010; The Pharma Letter, 1996). Between manufacturers 
to pharmacies, via wholesalers, there is a free market price setting, but the price revision set 
by the government control these prices as it lowers the reimbursement price for end customers 
(Iizuka, 2008). Price revisions have made the pharmaceutical market more competitive, 
forcing wholesalers to work under higher cost pressure (The Pharma Letter, 1996).   
In 1990, the Japanese government decided to change their approach in reviewing drug prices. 
Prior to the 1990s, the price revision was reviewed on just the top 10 percent or 19 percent of 
most expensive drugs, making companies selling their pharmaceuticals for higher prices at 
these percentage levels to prevent a decrease in end prices and selling the rest of their volume 
at lower prices (Umemura, 2011).   
In 1991 an update to the price revision was done by changing the way to calculate prices in a 
way determined by the weighted average price of all drugs (Umemura, 2011). This was done 
in order to promote innovative drugs and to reflect real market prices, avoid fluctuations and 
making the drug pricing easier (JPMA, 2015b).  
The entry price is decided on substitute drugs that exist on the market. As innovation is 
encouraged, drugs who are safer and more efficient than other drugs on the market will be 
rewarded with a premium price that will be up to 100 percent more than the existing ones. 
Between 2008-2014, four price revisions were made, and on average the price reductions on 
the top 10 selling drugs in Japan fell with 19 percent (EvaluatePharma, 2015)  
28 
 
4.5.3 Price Revision impact on wholesalers   
Between 2008 and 2014, the NHI price revision has reduced prices on prescription drugs by 
between 4.2 percent and 6.2 percent (EvaluatePharma, 2015). This year's revision is expected 
to land on 7 percent according to Mr. Urakabe.  
Wholesalers who are the intermediate actors, between manufacturers and medical institutions 
has difficulties to raise their profitability (R&I, 2015). Manufacturers are the ones who can 
control this best by not cutting their part of the cake as much as the price revision does. This 
means that the margin gap to earn money for pharmacies/doctors/hospitals and wholesalers 
decreases. Pharmacies and doctors do often have more than one wholesaler they are 
negotiating with, which means that in the price revision aspect, the wholesalers are very 
exposed (Reed Maurer, 2011)  
Many drugs are priced at a high level due to its efficiency and safety. Wholesalers want to 
secure that these drugs are being delivered by them and trying to reach exclusive agreements 
with the manufacturers producing the high priced drugs, in order to reach higher margins and 
profits, according to Mr. Deguchi. The introduction of a product for Hepatitis C by an 
American manufacturer was given a very high NHI reimbursement price which made 
wholesalers trying to get exclusive agreement for the sales of this drug, Mr. Ooi says. He adds 
that an exclusive agreement with one wholesaler was not reached. However, only three 
wholesalers; Toho and Suzuken from the big four, together with another wholesaler, were 
able to reach agreements to distribute the drug on the Japanese market.    
4.5.4 Lower inventory margins affect on wholesalers   
Wholesalers have seen the period between March and April as a profitable period as there 
have been an arbitrage opportunity for them (IFPW, 2016a). As the NHI price revision makes 
the prices effective from 1
st
 of April, the norm has been for wholesalers to buy from 
manufacturers at new invoice prices on 1
st
 of March. This price revision between 
manufacturers and wholesalers is a response to the NHI price revision made on the customers 
price of the drug. It has the same function as the NHI reimbursement price revision, as it 
lowers prices on drugs. The lower price implemented between manufacturers and wholesalers, 
a month before the revised prices for customers being activated, have made wholesalers being 
able to buy drugs for a lower price from manufacturers, but sell at the old higher prices to 
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pharmacies, hospitals, and clinics. This has made the margins higher during this period, and 
the extra margin due to the difference between the new price they buy from manufacturers 
and the old price they sell it on, is called the inventory margin (Pharma Japan Web, 2016).  
The inventory margin has been a big income source for wholesalers, estimated income from 
the inventory margins for the big four are; more than 5 billion yen each year when it comes to 
Alfresa Holdings and Medipal, while it is over 4 billion yen for Suzuken, and around 3 billion 
yen for Toho (Pharma Japan Web, 2016).    
From 2016, the inventory margin will decrease as 8 of the top 12 manufacturers in Japan will 
delay the price revision from the beginning of March to the middle of March. The reason 
behind this change is that manufacturers have had very few orders by the end of February 
over the years when the price revision was going to be made, while the orders were massive 
on the 1
st
 of March as wholesalers saw an arbitrage opportunity to increase their inventory 
margins. Manufacturers saw this as a risk as there might be a disaster causing problems and 
shortages in the wholesalers inventories. Wholesalers have, from some manufacturers, 
received refund for drugs remaining on the 1st of March covering the old higher price and the 
new invoice price (Pharma Japan Web, 2016).   
This move by manufacturers is also made because of the more frequent NHI price revision 
(Pacific Bridge Medical, 2015; Pharma Japan Web, 2016). Manufacturers will see their prices 
decrease and are therefore not keen to offer the margins to wholesalers and therefore some of 
the biggest manufacturers delay the price adjustment with half a month (Pharma Japan Web, 
2016).   
4.5.5 Generic drugs     
A way for the Japanese government to keep the expenditures down is to promote the use of 
generic drugs (IHS, 2015). These drugs are copied versions of the original branded drugs that 
have the same effect on the patient and are as safe, but the generics are cheaper (Bloomberg, 
2016; MarketLine, 2016; MHLW, 2012).  
As the generic drugs importance in the Japanese market will rise for every year, the 
importance of generics for wholesalers will increase. Lower margins on generics, compared to 
original drugs, means that the volume of sales need to increase to make profits (JCR, 2011). 
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Mr. Nagao confirms that the decrease of prices lead to lower margins and an increase in sales 
volume. He adds that it leads to a higher distribution volume, and emphasis on how the 
generic drugs add to an increased distribution burden for wholesalers.  
 
Figure 3: Past and expected share of generic drugs in Japan. (Bloomberg, 2016). 
In the early 1990’s the prices for the new generic drugs had the same listing prices as branded 
pharmaceuticals. A change in 1994 by the MHLW would however reduce the prices of the 
newly introduced generics to 90 percent of the price of branded pharmaceuticals. After 1994, 
the prices of generics have further been lowered. In 1996 the prices were lowered to 80 
percent and in 2004 lowered to 70 percent (Jakovljevic et al., 2014). Today the generics 
introduction prices are set at 60 percent of the original drug and 50 percent if 10 products are 
introduced with the same effect (IFPW, 2015a).   
In the past, there were difficulties for manufacturers of generic drugs to connect with the 
pharmaceutical wholesalers as the wholesalers were mostly interested in the branded drugs. 
The task wasn’t made easier as the wholesalers had problems in finding customers as 
uncertainties existed around the generics (Jakovljevic et al, 2014). In 2006, generics share of 
the pharmaceutical market was 17 percent (JFTC, 2006). However, in later years there has 
been a significant increase of generic drugs as a portion of all prescription pharmaceuticals 
(JFTC, 2014). In 2014 the volume share of generics was 58.1 percent (International Business 
Publications, 2016). In 2020 the government's goal is to achieve a rate of 80 percent or more 
of generics share of drugs (JGA, 2015; IHS, 2015).  
Though the volume is high, the sales numbers are not as high. In 2014, generics value on the 
Japanese pharmaceutical market accounted for 1059 billion yen, compared with the total 
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pharmaceutical market value of 9 055 billion yen (Orbis, 2016). However, spending on 
pharmaceuticals in Japan is expected to increase 3-4 percent the coming five years with the 
generic market expected to grow 10 percent per year (Bloomberg, 2016).  
One of the reasons behind Japan's low share of generic drugs in the past was due to the 
uncertainty from health care professionals and medical institutions that had difficulties in 
trusting the drugs quality, supply and information (Hasegawa, 2012; JFTC, 2006). Another 
reason is when generics enter the market, the price of the original product decreases as well, 
and as customers only pay maximum 30 percent of the drug's price, the savings for customers 
are not big enough in order to choose generics over original drugs (Reed Maurer, 2013b). 
Japanese customers have also a custom of being loyal to brand named drugs (Jakovljevic et. 
al, 2014).  However, the Japanese government has dealt with this problem when they in 2007 
initiated the "Action Plan to encourage Generic drug use" which main focus was to secure to 
keep a stable supply of the drugs, make sure the generics are of high quality and to provide 
information about the drugs both to medical professionals and the public (Yoshida and 
Toumi, 2012). Further actions taken to increase the acceptance of generic drugs are taken 
through different "action programs". These actions have improved the awareness of generic 
drugs for patients (Hasegawa, 2012).   
4.5.6 Generics impact on wholesalers  
The shift from branded drugs towards generic drugs means big problems for pharmaceutical 
wholesalers, as they have been extracting most of their money from the higher margin 
branded drugs. Even though the wholesalers sell more generic products now than before, it is 
the products low prices and the high cost of distributing several brands that creates an issue 
(IFPW, 2015a). As Taisuke Murai, the chairman of JPWA's Research Committee for 
International Pharmaceutical Distribution, says the price of the generic drugs is low, though 
the transport cost of generic drugs is the same as for original drugs. The increase of generic 
drugs will mean more frequent distribution for wholesalers which will result in higher costs. 
He mentions that wholesalers want to avoid distribution of products worth $500 where the 
distribution cost will be $1000 (IFPW, 2016b).   
As the sale in volume of generics increase, the value of the sales becomes lower. When 
generic drugs of a branded drug are released, the amount of products is raised by around 15 to 
20 times making it difficult to store all the drugs in the distribution centers (IFPW, 2015a). 
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Dr. Nakamura emphasis the problem wholesalers face with the introduction of generics as the 
amount of drugs will lead to the need of expanding distribution centers which will raise the 
costs for wholesalers. It is estimated that nearly 50 percent of the inventory in distribution 
centers is being taken up by generics, even though the wholesalers sales ratio of the drugs is 
not even 10 percent (IFPW, 2015a). However, wholesalers are able to select which generic 
drug manufacturers they want to work with, and often they do not choose all 15-20 generic 
drugs which occur per original drug, Mr. Oikawa says. He adds that Odashima expects that 
the generic drugs per original drug will decrease in the future to a level of around five generic 
drugs per original drug, which will make wholesalers able to cope with the physical storage 
space needed because of generic drugs. In 2014 Medipal's share of generics was 7.9 percent, 
while in 2015 the generics share was 9.4 percent. In the case of Toho, the generics share in 
2014 was 8.9 percent, and in 2015 9.9 percent (IFPW, 2015a).  
The increase of generic drugs raises the information providing burden for MSs. As MSs 
provide information about a lot of different drugs, their knowledge is not as deep as MRs 
from manufacturers. However, the MRs are not allowed to compare their own drug with 
others, which mean that it is up to MSs to provide the comparison information about different 
generic drugs. With the huge increase of generic drugs on the market, it will be difficult for 
MSs to provide the necessary information about generic drugs to medical institutions, Dr. 
Nakamura says.   
Dr. Nakamura mentions how wholesalers delegate specialized tasks to subsidiaries, for 
example subsidiaries who focus on distribution only in order to reduce costs, leaving the 
information providing to MSs. Mr. Deguchi says that MRs promote their own product as it is 
not allowed for them to compare their own product with other manufacturers. It is MSs role to 
provide comparing data of generics to assist pharmacies and doctors in their choice of generic 
drugs. Mr. Nagao adds that the ongoing search for efficiency is contributing to even lower 
margins.  
With the lower reimbursement price on generic drugs affecting wholesalers profit, it is 
difficult for wholesalers to afford to expand in scale as they need more distribution space to 
store the generic drugs, Mr. Deguchi says. He adds that wholesalers try to reduce the number 
of different generic drugs they deal with and try to reach exclusive agreements with certain 
generic manufacturers and exclude others.  
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Though, the exclusive agreement is harder said than done. Mr. Deguchi mentions how Toho 
started an exclusive agreement with a generic drug manufacturer to deliver and promote their 
drugs and excluded other generic drugs in order to ease the burden of handling the generic 
drugs. This exclusive agreement did not end well as the acceptance of generic drugs at 
hospitals and clinics around Japan differed, whereas some clinics and hospital preferred 
branded drugs over generic drugs, as they did not believe the quality of generic drugs was as 
high as the original branded drugs. This made the promotion from the exclusive agreement 
difficult according to Mr. Deguchi.     
4.5.7 The separation of prescription and dispensing  
Another reason contributing to the high cost structure is the prescription versus dispensing 
problem. In an effort to increase profits, medical institutions prescribe and dispense an 
unnecessary volume of drugs. The government tries to solve this by splitting prescription and 
dispensing into two separate parts (Wuemura, 2004).   
The government wants the physicians to prescribe drugs and move the dispensing operations 
to independent pharmacies who provide drugs to customers based on guidance from 
physician's description (Suzuken, 2014). In 1986, 9.7 percent of the drugs were prescribed by 
a doctor and dispensed by a pharmacy. In 1995, it was 20.3 percent (Wuemura, 2004) and in 
2009 that share was 50 percent each (Nakamura, 2013). In 2013, 2/3 of the dispensing is done 
outside hospitals (Jakovljevic et al., 2014). This is something Mr. Ooi at Ferring 
Pharmaceuticals confirms as he says the pharmacies are buying the manufacturers goods in an 
even higher grade every year from wholesalers, instead of hospitals whose share is decreasing 
which is something that has led to pharmacies getting together in chains to increase their 
buying power. Mr. Oikawa emphasizes the importance for wholesalers to keep good relations 
with pharmacies. 
4.5.8 Prescription and dispensing, effect on wholesalers  
Before the prescription versus dispensing goal, wholesalers mainly delivered drugs to medical 
institutions as they were the ones who did both the prescribing and distribution (Nakamura, 
2010). The prescription versus dispensing goal has made more pharmacies join the ranks of 
delivery points for wholesalers. With more delivery points wholesalers need to be more 
efficient with deliveries and negotiation of drugs (Nakamura, 2010). Mr. Oikawa says that the 
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increase in delivery points mean that wholesalers need to reduce costs by themselves which is 
a reason to the separation of information provision for MSs and deliveries to delivery 
specialists.  
In 2010, there were around 230 000 delivery points for Japan's wholesalers to cover (JPWA, 
2010). This has changed wholesalers sales channel's focus more towards pharmacies (Alfresa, 
2005). For example pharmacies share of Suzuken's sale have been increasing steadily. In 2001 
it was around 30 percent, that number was more than 50 percent in 2014 (Suzuken, 2014). 
The many branch offices spread out around Japan help wholesalers control the increase of 
delivery points, as they  contribute to shorter lead times (MHLW, 2007; Nakamura, 2013). 
According to Dr. Nakamura, the supply chain is being inefficient as Japanese wholesalers 
need to meet the requirements of many customers spread out the country in different delivery 
points. He says that the optimal would be to develop the supply chain based on regular 
delivery from one or two distribution centers. Though, he emphasis the difficulties due to 
customers who request irregular delivery, and in an effort to satisfy the customers, 
wholesalers need to be spread out over the country to be able to respond fast, otherwise the 
customer might choose another wholesaler.   
Dr. Nakamura further mentions that wholesalers are taking care of returning products, and this 
contributes to the need of being located close to customers. The behavior raises the 
distribution costs including delivery costs and investment costs for additional distribution 
centers. Inefficient, yet a sensitive response to the need is a main feature of Japanese supply 
chain.   
4.6 How the wholesalers have responded to the external factors  
4.6.1 The importance of added value  
A way for wholesalers to respond to lower margins is to add value as complementary to the 
core business (Nakamura, 2010; PharmAsia, 2013; Reed Maurer, 2011). Wholesalers started 
to think outside the box, and not only trying to do what was expected from them, to deliver 
and promote drugs, but to offer something extra outside their core business (Reed Maurer, 
2011). Added value leads to a higher profit and a bigger share of pharmaceutical companies 
as the added value increase the interaction and business between them, Mr. Deguchi says. 
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Kunio Fukujin, the then CEO of Alfresa, mentioned in 2005 that changes in the 
environmental will force wholesalers to offer added value (Alfresa, 2005).  
Wholesalers had, and still have, different strategies in their use of added value, Dr. Nakamura 
says. He emphasizes the importance for wholesalers to differentiate from each other as they 
nowadays have similar product ranges which derives from the consolidations of the 
wholesalers business. It is not easy for the wholesalers to differentiate themselves (R&I, 
2015). Either they try to add value by focusing on low cost operations where they try to keep 
the stock down, downsize deliveries, and automatize tasks where it is possible. The other way 
is through high added value where focus is on tailor its services to the demand of customers, 
Dr. Nakamura adds. Added value created by carrying information is something most of the 
wholesalers do as they have contact with all buyers, which MRs from manufacturers do not 
have (Reed Maurer, 2011).  
Dr. Nakamura mentions that added value through low cost operations give lower margins 
compared to wholesalers with focus on specialized high added value. If the distributor's added 
value is considered low, it is of great importance to have a high sales volume (Celly and 
Frazier, 1996).   
4.6.2 ICT  
The old view of wholesalers only doing distribution and sales promotion is getting outdated 
due to the introduction of ICT (Nakamura, 2010). ICT is being used in business to business 
relationships through electronical systems (Maruyama, 2004). The development of ICT as 
added value has made a restructure in the distribution system, as “the wholesale business 
model has shifted from focus on integrated sales promotion and delivery services to one that 
separates the two roles” (Nakamura, 2010:67). Services containing ICT have large initial 
investment costs (Nakamura, 2010).   
The evolution of ICT has contributed to the decrease of wholesalers and shorter distribution 
channels (Hashimoto, 2003). For example, orders done by telephone have higher costs due to 
the immediate response it requires. Electronical orders through point of sales-systems give 
wholesalers better control of customers inventory as they constantly have information about 
their inventories. This lower lead times and decreases the need of branch offices, a change 
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through the use of ICT that lower costs in the long term and increases control, according to 
Dr. Nakamura.   
A further reason for wholesalers to implement an electronic order system is to reduce the 
number of mistakes, according to Mr. Oikawa. He adds that electronic orders give 
wholesalers the opportunity to prepare deliveries on a periodical basis, instead of order 
through phone where the response needs to be immediate.   
ICT has led to integration of distribution centers through automatization of operations in 
available areas, like orders and pickup, leading to a reduced work force. The information will 
flow faster through ICT and enable the time between order acceptance and sorting to 
decrease, something that will lead to wholesalers cover a bigger area (Hashimoto, 2003).    
Dr. Nakamura mentions that the big four wholesalers all have shifted to ICT, though they use 
it in different ways, either with a low cost strategy or through a specialized high added value 
strategy. ICT in low cost operations is used in a way to keep the product stock as low as 
possible, automatization of tasks where it is possible, and periodical deliveries. With a 
specialized high value strategy, wholesalers tailor its services to the customers demand, for 
example the frequency of deliveries.    
We will present how the big four wholesale groups use added value in their operations:  
4.6.3 Toho added value   
Dr. Nakamura says that Toho has made an improvement in their ordering system through the 
introduction of ICT. Toho has implemented a point of sales system with electronical orders 
that are connected with their customers. This system is called ENIF, and has given Toho a 
competitive advantage when it comes to order system as it has made operations more 
efficient, for example through lower lead time. Toho experienced large initial investment 
costs when introducing ENIF. The investment carried a high risk as the contributed extra 
added value is low, Dr. Nakamura says. Therefore, it is important for wholesalers to get long 
term profit in return from investments (Nakamura, 2010).   
Toho's main focus when it comes to added value is on the users, and especially on 
pharmacies, according to Dr. Nakamura. With the limited space at pharmacies, Toho offer 
frequent deliveries where they with the use of ENIF system instantly get information about 
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the current stock volume and what kind of products that are sold at a certain pharmacy. With 
the ENIF system, Toho can easily meet the demand of just-in-time services to pharmacies 
according to Dr. Nakamura. The point of sales system reduces the risk for uncertainty relating 
to the market and inventories (Hashimoto, 2003).  
Japan Pharmaceutical Association did, in 1997 and 1998, an investigation on how pharmacies 
could handle small packages delivered by manufacturers via wholesalers. MHLW has set a 
standard on how big the small packages are. The investigation found that in 1555 cases, the 
pharmacies could not obtain the amount of drugs delivered on a routine basis, due to too small 
shelves. As a respond, Toho started to offer "divided package sales" which referring to 
repackage of the drugs that Toho received from manufacturers and made new packages with 
smaller amounts to fit the requirement that pharmacies need (Shiragami et al., 2001).  
In 1997 Toho also developed and introduced ENIF when a hospital in Kawasaki City decided 
to switch the dispensing operations to pharmacies (Nakamura, 2010). Pharmacies place 
electronic orders through scanning bar codes with help from a mobile terminal to Toho whose 
response is immediate as they deliver the required amount to pharmacies, Dr. Nakamura says. 
As a single pharmacy do not need the same amount as big hospitals, the development of the 
ordering system included orders that were repacked to contain smaller amounts. This system 
enabled Toho to offer instant delivery, and as the system proved to give more orders than 
expected, Toho started to use motorbike courier service to faster deliver drugs to pharmacies 
(Nakamura, 2010).  
Toho offered this added value service as a pharmacy for pharmacies. The pharmacy handles 
2400 different prescription drugs and Toho delivers to pharmacies included in the ENIF 
system (Shiragami et al., 2001). According to Dr. Nakamura, nowadays 30 000 pharmacies 
have an arrangement with Toho over the use of ENIF.   
This point of sales system decreases lead time and as Toho have many small distribution 
centers, especially in big cities, the distance between distribution centers and pharmacies 
becomes very short. Though, Dr. Nakamura points out a problem with the rural areas as it is 
not as easy to use this delivery system due to the lower density of pharmacies. This added 
value provides a small profit for Toho according to Dr. Nakamura. The introduction of 
"divided package sales" means increase in the delivery frequency as pharmacies cannot hold 
big stocks. Frequent deliveries means higher costs, and as "divided package sales" include 
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fewer amount of drugs, the delivery cost might be more expensive than the worth of drugs 
(Shiragami et al., 2001).  
By implementing the ENIF system Toho saw an opportunity to lower costs, as ENIF system 
contributes to better control over pharmacies stock, Toho can thereby prepare deliveries 
during night and deliver to pharmacies early in the morning, Dr. Nakamura says.   
4.6.4 Suzuken added value  
Suzuken offer distribution tailored for its customer, all the way from manufactuerers to 
medical institutions and pharmacies. Most common for wholesalers is to offer distribution 
from wholesalers to medical institutions and pharmacies. With special products that need 
special treatment, Suzuken offer such controls as low temperature treatment during the 
distribution of the drug Dr. Nakamura says. He emphasizes Suzuken's efforts with orphan 
drugs, which have few users, where they offer the help for limited hospitals to deal with these 
drugs.   
Suzuken have a high capability when it comes to marketing function. They were the first one 
to implement performance fees on manufactureres for work done by their MSs (R&I, 2015). 
Suzuken group are trying to become the wholesale leader in Japan through a goal where they 
"are switching from competing in the same services as rivals to competing in capabilities, and 
are building a framework that can respond flexibly to changes in the environment" (Suzuken, 
n.d: para 4).  
To reach their goal, they are implementing medium-term growth strategies. In between 2011-
2014, the growth strategy was to add value to its customers by increase the visiting frequency 
in order to build stronger relationship and decrease the distance between them. This strategy 
was based on the idea that all wholesalers have the same product range, and by building 
stronger ties with customers, Suzuken saw this as an opportunity to differentiate (Suzuken, 
2014).  
By focusing on each single customer, Suzuken customize their MSs services after the need of 
customers. They also increased their logistics sales force, introduced in 2011, with focus on 
pharmacy orders and deliveries in order to make the sales system efficient, as frequent 
deliveries with a small amount is increasing due to pharmacies demand (Suzuken, 2014).    
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4.6.5 Alfresa added value  
Wholesalers must be able to provide information about the markets to manufacturers in order 
to be selected. Kunio Fukujin, the former Alfresa CEO mentioned the need of added value, 
from providing information about drugs, to assist management at pharmacies (Alfresa, 
2005).    
Alfresa focus on low cost operations where reducing costs by reducing labour, separation of 
MSs role, and automatization is common tools, Mr. Urakabe says. Other ways to reduce costs 
for Alfresa is through periodical deliveries many times a day, and specializing, says Dr. 
Nakamura. For example, Alfresa employ part time workers or female drivers to deliver 
products as they generally have lower salary than men in Japan. These deliveries have made 
MSs to focus on promotion of drugs and handed over the role of distribution to Hitachi who 
become delivery specialists, says Mr. Urakabe. Hitachi and Alfresa had entered into a joint 
venture prior to the separation of MSs role. The joint venture's reason was to evolve payment 
and distribution operations, as Hitachi had previous experience with SAP operations which 
Alfresa could implement after the joint venture and by that reach lower costs.    
Mr. Urakabe mention that further ways to decrease costs is to implement electronic ordering 
system. Today they have around 60 percent of orders made electronically but they want to 
increase that number to 100 percent. By receiving electronic orders, Alfresa will be able to 
prepare deliveries on a periodical basis with preparation during night times and deliveries in 
the morning, and thereby reduce the need of the 200 different branch offices, and rather 
deliver direct from one of the 22 distribution centers. An important differentiation for Alfresa 
is the logistics where they deliver either through direct deliveries from distribution centers 
which is 0.6 times the cost as the indirect deliveries through branch offices, he adds. Today 
Alfresa have 70 percent of their deliveries through branch offices.   
Another added value is the special distribution of products with need of special temperature 
during transport. Alfresa provide special logistic technology with freeze boxes, where they 
offer low temperature distribution that lasts for more than 100 hours in order to specialize on 
orphan drugs, Mr. Urakabe says.   
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4.6.6 Medipal added value 
Medipal and Alfresa are both trying to use added value in order to have a low cost strategy 
Mr. Deguchi says. By reducing the number of deliveries of products, Medipal are able to 
lower costs. They are able to reduce the number of deliveries by the installation of branch 
offices inside big distribution centers and can therefore reduce steps in the delivery of 
products.  
These distribution centers are called Area Logistic Centers (ALC) and are located in urban 
centers where most of its customers are located. ALCs location in the urban is different from 
other wholesalers distribution centers who often is located in suburban with branch offices in 
different local contexts. In ALCs, all products offered by Medipal are represented and can be 
distributed to customers directly instead of going through a local branch office. These centers 
do daily distribution four times a day. Today Medipal have six ALCs represented, with a 
further three planned to be built. These ALCs will be automatized as much as possible to 
increase efficiency and lower costs (Medipal, 2016a). The integrated logistics system made 
through the automatization of ALCs enables its customers to manage inventory efficiently 
(R&I, 2015). Mr. Nagao adds that, in the future, the most important thing is how efficiently 
the business is being done, and how automatization of system to reduce labour is a big target 
for Medipal.  
As MSs role have been narrowed through, for example the automatization of payment or the 
role of delivery specialists, has given Medipal room to add value through the use of Assistant 
Representatives (ARs), Mr. Nagao says. Through education, Medipal have further educated 
MSs to become ARs to increase their marketing expertise (Medipal, 2016b; R&I, 2015). As 
Medipal expresses, the communication between MSs and doctors/medical professionals is 
very important  for the information exchange, and by educating MSs to ARs, Medipal want to 
evolve the gathering and dissemination of information by educate MSs to learn more about 
diseases and pharmaceutical products (Medipal, 2016b). The company has around 1800 
people, which according to Mr. Nagao is half of the MSs workforce at Medipal, that have 
been further educated in Medical representatives (MRs) exams, making their knowledge even 
broader adding more value to the business as they become ARs.  
The ARs receive deep knowledge about drugs which make them a valuable resource for 
manufacturers. Their knowledge provide more detailed information about drugs. In addition, 
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they provide post market surveys and handle drugs with adverse reaction, Mr Nagao says. The 
ARs will for example help foreign companies establish on the Japanese market by providing 
the MRs role through ARs. Foreign companies often lack the cultural knowledge which is 
very important in Japan, something that ARs will help them cope with.    
According to Dr. Nakamura, this is a way for Medipal to be attractive for manufacturers as 
they will reduce costs for manufacturers by using more ARs as complementary for MRs as the 
wages of ARs is lower. Around 60 percent of Alfresa's costs are generated from labour, so 
their costs will not decrease through education of MSs, though they will receive more 
customers and a sales promotion fee from manufacturers for doing the job cheaper than MRs 
would, which will lead to an increase in margins Dr. Nakamura says.   
 
Figure 4: The role of Assistant representatives. (Medipal, 2016b). 
To start a sales organization in Japan costs a lot of money. Medipal provides a contract sales 
organization as a solution for that problem. By an agreement, Medipal do marketing and sales 
for the contractual part, which is another way to add value by Medipal, Mr. Deguchi says. 
4.6.7 The need of extending the core business  
The main income from the core business for wholesalers has been the drug margin that is 
calculated as the difference between the price they pay to pharmaceutical manufactures and 
the price they sell to medical institutions. Though, after the deregulations and reorganizations, 
this is not the case anymore (JCR, 2011).   
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With NHI price revision revised downward, in combination with the government's goal to 
increase the share of generic drugs as well as the prescription vs dispensing goal, makes the 
profits shrink for wholesalers. This gives rise to the need of other profit sources than 
wholesalers core business, Mr. Deguchi mentions. Wholesalers differentiation into 
manufacturing and pharmacy operations is seen as an opportunity as the margins in those 
parts of the value chain is higher (Nakamura, 2013). Alfresa's mid-term goal have changed 
from M&As and expanding geographical area, to expand business area by focusing on 
manufacturing and pharmacy business, and also try to expand to foreign countries, Mr. 
Urakabe says. He adds that 80 percent of their business is wholesale business. The share of 
other income sources are limited due to the focus on their core business, though, the 
prescription drugs are generating a stable income (R&I, 2015). By expanding to other 
business segments, the margins for wholesalers do not increase, though the profit is being 
generated from more than only the wholesalers core business, Mr. Deguchi says.   
For example, Suzuken was early to diversify into other segments and have built up a strong 
manufacturing base providing stable income. Through M&As, they expand into different 
areas when it comes to health care, for example they are involved in insurance pharmacy and 
nursing care. The income sources for Suzuken are rising from other segments than their core 
business (R&I, 2015).   
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5. Analysis 
This chapter will present an analysis of the empirical findings which also will be discussed 
together with the report's theoretical framework, and the earlier research done.  
This thesis has investigated how external factors affect the Japanese pharmaceutical 
wholesalers. Like Scott (2008) says, institutions change under external factors. This has been 
a clear characteristic in the organizational field of pharmaceuticals wholesalers in Japan. 
External factors like political, social, and economic are forcing wholesalers to adapt to 
demands. The most evident demand is the government’s different efforts in order to lower 
health care costs.   
Big wholesalers are shaping the industry and forcing smaller actors to make changes, mainly 
through entering into M&As with them. It is evident how consolidations on a horizontal level 
have made the distribution chain shorter, just as Maruyama (2004) predicted. Though, in 
some areas it is found that local wholesalers are stronger than the big four wholesaler groups 
due to strong local ties. The broader picture shows a clear characteristic of coercive 
isomorphism as the big wholesalers with big power put pressure on smaller wholesalers to 
change. Therefore, the presence of smaller wholesalers with strong local ties both confirm and 
questions Meyer's and Rowan's (1977) findings that smaller players in the organizational field 
have to adapt to its surrounding in order to survive in the future.   
5.1 A market with two faces  
In order to remain competitive and survive, there is a clear trend in the industry that 
wholesalers become more homogenized, as DiMaggio and Powell's (1983) concept of 
isomorphism indicates.  
North (1990) mentions how institutions are the rules and organizations are the players in a 
game. This is something that correlates with the Japanese pharmaceutical market where the 
government makes changes in order to keep the costs down which affect wholesalers heavily 
with the need to respond by expanding their business area and offer service outside their core 
business. The trend in the pharmaceutical industry is in line with what Meyer and Rowan 
(1977) stated that by becoming alike its environment organizations receive legitimacy and 
will survive.   
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Consolidations have made the number of wholesalers’ actors to decrease from 1200 in 1970 
to just over a 100 today. Within the core business, the focus has been on price pressing to 
remain competitive. For example, all wholesalers acquired or merged by Alfresa work under 
the same low cost strategy which increases the dependency for smaller wholesalers to work 
under the guidelines made by Alfresa. This is in line with what DiMaggio and Powell (1983) 
mention, that the higher dependency there are between organizations, the more alike they will 
become each other as a result of coercive isomorphism. As the size of pharmaceutical 
wholesalers increased and focus shifted towards regional and national level, the focus 
changed towards customers, which correlates with the earlier research by Maruyama (2004) 
who emphasis how the role have changed from sales agents for manufacturers to buying 
agents for customers.  
It is evident how wholesalers’ business pattern mainly has changed in the same direction. The 
goal of the generic drugs, separation of prescription and dispensing, and introduction of ICT 
have all been contributing to the specializing role of MSs, something that is seen as necessary 
due to the lower cost structure in the industry. This change correlates with DiMaggio and 
Powell's (1983) concept of how normative isomorphism leads to professionals at 
organizations act in similar ways.  
DiMaggio and Powell (1983) found out how isomorphism does not necessarily mean more 
efficient organizations, which is evident in the case of Medipal where Mr. Nagao mentions 
how M&As did not mean higher efficiency nor profits, but they received human resources and 
an increased professional network which resembles to normative isomorphism.  
Even though the main pattern in the industry is towards isomorphism, there is evidence that 
points against isomorphism. For example, the big four wholesale groups find it difficult to 
enter specific areas due to the strength of local wholesalers who do not enter into 
consolidations with big wholesalers, as local ties with medical institutions and pharmacies are 
highly valued. The market is not only focused on a national level by the big four with its 
group companies but also represented with local wholesalers. This goes in line with the 
critique towards isomorphism where Beckert (2010) mentioned how isomorphism only 
focusing on one side of the coin and not pays attention to divergence.  
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5.2 Expanding business segment and change in supply channels  
This year's higher expected price revision, together with reduce of inventory margins will 
further increase pressure on wholesalers to find alternative income sources. The price pressing 
strategies are not seen as sustainable. The emphasis on alternative income sources cannot be 
understated and this will accelerate the need for wholesalers to diversify their business 
domain. As Nakamura (2010) concludes, without deliveries of health care services and 
business solutions outside their basic wholesale function, they will not survive. The inventory 
margins cut is evident from coercive isomorphism where higher price cuts from the 
pharmaceutical manufacturers, with bigger influence, lead to lower margins for wholesalers.   
Alfresa's change in their mid-term goal to extend their business domain towards pharmacy 
and manufacture operations has until today resulted in that 20 percent of their operations are 
outside their core business.  What is evident is how wholesalers strategies differ when it 
comes to expanding business domain with Medipal only operating within the wholesale 
business while Alfresa’s business domain is widen to include both pharmacies and drug 
manufacturing. This goes both in line and questions Nakamura's (2010) findings of the 
importance to find other business segments in order to survive.   
The increasing amount of delivery spots due to more dispensing for pharmacies is a future 
challenge for wholesalers, as the power relationship between wholesalers and pharmacies 
changes, in favor of pharmacies. As Mr. Urakabe says, Alfresa's sales channels will focus 
more on dispensing pharmacies. Suzuken seems to follow in the footsteps as more than 50 
percent of its customers are pharmacies. More delivery spots and pharmacies will make 
wholesalers even more exposed. The pharmacies option to choose between different 
wholesalers due to the same product supply increases the importance for wholesalers to make 
distribution more efficient. As North (1990) mentioned, historical choices affect decisions 
being made. Pharmacies increase in bargaining power can be related to what happened with 
wholesalers as they merged together to further increase their power.  
5.3 A trend towards exclusive agreements  
Embodied in the price revision is the innovation premium. It is likely that drugs that are 
reimbursed at a rate of up to 100 percent more than other drugs will lead to wholesalers trying 
to reach exclusive distribution agreement with that specific pharmaceutical manufacturer. 
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Maruyama (2004) discussed how exclusive agreements occur from consolidations, which can 
be questioned. The introduction of the Hepatitis C drug on the Japanese market did not lead to 
an exclusive agreement, even with the big four presence and coverage of the whole Japanese 
market. Exclusive agreements for pharmaceutical wholesalers occur from drugs receiving 
higher reimbursement price than others.   
As described by North (1990), uncertainty exists due to the complex problems that can arise 
in the environment. The changing demographic in Japan is a complex problem for the nation 
itself, but even though this has led to an increase in generics, which is beneficial to keep 
health care costs down for the government, it creates a complex problem for pharmaceutical 
wholesalers. Financial difficulties are expected to increase, for example the extra volume that 
need to be sold due to lower margins, and the storage space it requires will increase the 
pressure on wholesalers to build extra distribution centers. The need of extending distribution 
centers in order to meet the storage demand of the huge amount of generic drugs will be 
difficult as many wholesalers will struggle to afford these initial investments.    
Exclusive agreements are evident with the introduction of generic drugs as wholesalers will 
increase the effort to sell innovative drugs at the expense of generic drugs. As Mr. Deguchi 
mentioned, wholesalers enter into exclusive agreements with few generic drug manufacturers. 
However, as described difficulties can arise with exclusive agreements such as the case of 
Toho’s generic agreement with a manufacturer due to the uncertainty that surrounds generic 
drugs. It is likely that these problems will decrease year by year as campaigns from the 
government will increase the knowledge and acceptance of generic drugs, which the 
campaign in 2007 is proof of. It is seen that the government's goal to reach a higher share of 
generic drugs and use policies like the 2007 campaign, and 2020 goal, influence all actors in 
the organizational field as it is aimed towards everyone. Therefore, if an actor, like a 
wholesaler, does not adapt to this policy they risk to be seen as non-legitimate from other 
actors in the field. The steady progress of generic drugs share of the market will decrease the 
problems relating to exclusive agreements of generic drugs which correlates with Meyer and 
Rowan's (1977) findings that institutional policies have led to wholesalers entering into 
exclusive agreements in order to survive and adapt to its surrounding, like governmental 
policies. Also, the increase of generic drugs in the pharmaceutical market questions the 
findings from Rawwas et al. (2008) that well-known brands are important for driving the 
inventory at wholesalers. Today half of the inventory at wholesalers is generic drugs, and the 
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volume continues to increase. The Japanese government has with their policies managed to 
lessen the uncertainty about the generic drugs. However, they have moved the uncertainty and 
placed it in the hands of the wholesalers who now have to face the problems instead.    
By entering into exclusive agreements, the decrease in burden means that MSs can develop 
deeper understanding related to the generic drugs they handle. The wholesalers are able to 
develop an expertise and idiosyncratic knowledge in the relationship and the organization will 
then rely on the manufacturer or distributor which will give advantages. This resembles what 
Williamson (1979) mentioned; if an organization choose a distributor, the manufacturer or 
distributor will develop an expertise in the service provided.  
5.4 The importance of added value 
Lower margins are characteristic for the pharmaceutical wholesale industry. Due to external 
forces mentioned, wholesalers have to add value in different ways to attract customers. The 
higher and more complex demand from pharmacies spread out around Japan puts high 
pressure on wholesalers, and in order to be the chosen wholesaler, one must distinguish 
themselves from the rest. This correlates with earlier findings by (Oswald and Boulton, 1995; 
Rawwas, 2008) of how wholesalers need to add value to their operations in order to increase 
performance.   
ICT for wholesalers has given wholesalers a new field of opportunities to explore and made 
the industry a lot more efficient. The kinds of ICT that are being used are different. 
Wholesalers whose ordering system is not electronic but rather manual, will receive orders 
when the stock at customers are empty, and therefore need to respond fast and have the 
required amount of drugs available, which lead to a speculative inventory management. 
Electronic order system makes it possible for wholesalers to be up to date with current stock 
at customers and can therefore prepare and control deliveries much more efficient. Maruyama 
(2004) discussed about a shift in inventory management, from a speculative to a 
postponement approach. The use of ICT and introduction of point of sales-systems have made 
it possible to increase efficiency through postponement inventory management. For example 
Toho’s ordering system, ENIF, has through the use of ICT changed from speculative 
inventory management to postponement inventory management. This has made them able to 
handle the inventory instantly and prepare for deliveries during nights and therefore they are 
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not as dependent on deliveries through branch offices, and can by that decrease costs, which 
Maruyama's (2004) earlier research justify.    
The increase in control and reduced lead time by ENIF leads to higher margins and more 
satisfied customers as Toho can meet the just-in-time demand. Alfresa who partly has 
implemented electronic ordering system which helps them conduct direct deliveries at 0.6 
times the costs as indirect deliveries through branch offices, and Medipal's use of automatized 
ALC's is evident of how ICT is growing stronger within the wholesale industry. This goes in 
line with earlier research where Hashimoto (2002) pointed out how investments in ICT 
prevent reduced efficiency while it also reduces lead time.  
5.5 Differentiation efforts  
Alfresa and Medipal conduct low cost strategies with focus on cutting costs is different from 
Toho and Suzuken's way of high added value. For example Alfresa with periodical deliveries, 
female drivers, and separation of tasks through specialization areas, is the opposite of 
Suzuken who tailor its business after customers demands, with frequent visits to doctors, 
increased logistics sales force to meet customers more complex requirements, a change in 
their logistic system, just as Maruyama (2004) found.   
Even though the big four wholesale groups purports to conduct a certain strategy, there are 
clear evidence of the opposite. For example Medipal who purports to add value through a low 
cost strategy has through the education of MSs to ARs a source that provide high added value. 
Mr. Nagao mentioned how ARs do not contributes to a lower cost structure within the 
company but rather add value by offering a more tailored business solution for customers with 
the introduction of ARs something that correlates to DiMaggio and Powell (1983) findings 
that organizations adapt to each other's strategies.  
Toho’s introduction of an electronic ordering system is being followed by Alfresa who also 
has introduced electronic order system to their operations. In the case of Suzuken, their 
special deliveries of orphan drugs have been adopted by Alfresa who also offer that service, 
though they do not offer the same distribution through the whole value chain. This shows a 
trend in the industry towards isomorphism relating to mimetic isomorphism, as Alfresa use 
solutions from other competitors. Further, DiMaggio and Powell (1983) state how strategies 
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used by a single organization within an industry are likely to be copied as the homogenization 
increases by time, something that is evident by the actions taken by Alfresa just mentioned.   
Medipal's use of the new ALCs can be an answer for inefficiency in the supply chain as Dr. 
Nakamura explained. The optimal situation would be to have regular deliveries from one or 
two distribution centers. With the ALCs, Medipal reduce the need of branch offices which 
lower the costs. However, as Dr. Nakamura mentioned, difficulties arise as customers are 
widespread throughout the country and complex demand from customers lead to difficulties 
as irregular deliveries are asked for. In line with Oswald and Boulton's (1995) study, Medipal 
has adapted their operations in order to cope with the low margin climate in the industry and 
used the ALCs as an innovative solution.  
The introduction of the ALCs with automatization technology provide fewer steps, shorter 
lead time and lower costs when distribute the product which confirms Hashimoto's (2002) 
discovery how the use of information technology reduce lead time. Interestingly, the usage of 
ALCs questions earlier research by Hashimoto (2003) as he discusses how distribution centers 
was going to be located in the suburban areas due to better traffic condition. However, the 
need to be efficient seems to have outdated this strategy as ALCs are located in urban areas to 
reduce branch offices which is possible through the use of ICT.   
5.6 Summary of analysis  
The pharmaceutical wholesale industry in Japan is experiencing a pattern of isomorphism 
where external factors force wholesalers to become more alike each other and adapting to its 
surrounding as described by Meyer and Rowan (1977). Also, uncertainty in the Japanese 
health care area has led to uncertainty making the government take actions which has created 
complex problems (North, 1990) for wholesalers by having to deal with lower margins. Even 
though the trend of M&As is clear in the industry, there are evidence of local wholesalers who 
are stronger than the big four wholesalers, which proves the relationship based nature of the 
Japanese society. In response to the lower margins, wholesalers try to add value in different 
ways to attract customers, though it is evident that efforts to differentiate in the organizational 
field is affected by isomorphism as wholesalers different strategies tend to overlap on each 
other's strategies. The price pressing strategies within the core business is not seen as 
sustainable and there is evidence of wholesalers expanding their business towards other 
business domains.   
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The trend in the wholesaler industry is towards exclusive agreements. The lower cost 
structure gives wholesalers incentives to enter into exclusive agreements in order to reach a 
higher profit. This is seen as a solution to the government's impact that hit wholesalers hard. 
Another trend is the presence of wholesalers in other business segments to avoid the low 
margins caused by external affects. Add to that the different kinds of added value, where ICT 
has played an important role as it has increased efficiency, and also contributed to a lower 
cost structure in the industry, and is seen as indispensable for the business in the future.  
Further, the main findings connected to DiMaggio and Powell's (1983) isomorphic 
mechanisms are:  
Coercive  
 Governmental pressures towards wholesalers due to social external factors like 
Japan’s demographic situation leading to measurements to reduce health care 
costs from the government. 
 Bigger forces pushing dependent organizations. Wholesale groups conduct M&As 
with smaller wholesalers.  
Mimetic  
 Through added value solutions and ICT innovations, wholesalers become more alike 
its competitors.  
Normative  
 Increased human resource network through M&As. 
 The specialized role of MSs. 
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6. Conclusions  
In our final chapter we will present our conclusions based on our research findings and 
analysis. We will also give suggestions for potential further research in the future about the 
studied area.  
This thesis have sought to answer the question: "How do external factors affect the Japanese 
pharmaceutical wholesale industry?".   
6.1 Empirical implications  
There are two clear ways the pharmaceutical wholesale industry has been affected by external 
pressures. First, the NHI price revision in combination with the generic drugs goal by the 
government leads to lower margins for wholesalers. This has led to wholesalers trying to enter 
into exclusive agreements. The reason to enter into exclusive agreements differs depending on 
which of the two external factors affecting. The NHI reimbursement price revision lead to 
lower margins, and therefore they want to reach an exclusive agreement with an innovative 
drug manufacturer in order to reach the premium and therefore higher margins. The generic 
drugs drive up costs for wholesalers and by reaching exclusive agreements, the wholesaler 
can reduce the burden of handling the huge amount of different generic drugs. The exclusive 
agreements will lead to a more reasonable handling of drugs for the wholesalers and the need 
of extra distribution centers will be overcome. The wholesale industry will see higher margins 
due to exclusive agreements.   
The second finding is how the increase of delivery spots due to the prescription vs dispensing 
goal by the government have increased the number and bargaining power of pharmacies. This 
has switched wholesalers sales channels focus more towards pharmacies. In order to cope 
with the weaker position, wholesalers have lowered their own cost structure. For the 
wholesale industry in general, this means tougher conditions as more delivery spots make the 
deliveries more complex. This has forced the wholesale industry to lower their cost structure 
in order to cope with the weaker position against pharmacies.   
These external effects have been met by the introduction of ICT which has been one of the 
most common tools as a respond to external factors.  By implementing ICT in their 
operations, wholesalers have increased the control, being able to use postponement inventory 
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management instead of speculative, and reduce costs by decreasing the use of branch offices. 
Wholesalers use ICT in different ways in order to make their operations more efficient, which 
have contributed to a lower cost structure in the industry. By either adding value through low 
cost operations or high added value, ICT gives wholesalers a competitive advantage. Even 
though the use of ICT has contributed to an even lower cost structure in the wholesale market, 
it is seen as indispensable for the business in the future. Just as Oswald and Boulton (1995) 
discussed in the problem discussion, technology was the solution in U.S., and is also the 
solution in Japan, in the form of ICT.   
6.2 Theoretical implications  
Using institutional theory as a framework to explain the research area has been useful in this 
study to understand how pharmaceutical wholesalers are being affected by surrounding 
external factors. As shown, this report has found external factors such as social, with the 
Japanese demographic situation, leading to political external factors from the government and 
the use of technology implemented in the wholesalers businesses. It is found how the 
pharmaceutical wholesale business in Japan is covered by uncertainties such as lower prices 
on drugs from the price revision and the increased use of generic drugs. Like North (1990) 
mentioned, institutions exist because of existing uncertainties and rules exist to reduce the 
uncertainty, but as this report has shown, uncertainty has entered the wholesalers business.   
DiMaggio and Powell's (1983) mechanisms of isomorphism fit well in the organizational field 
that has been studied. Most evident of the three mechanisms has been coercive isomorphism 
where stronger forces, such as the explained actions by the Japanese government and the 
M&As that has occurred. Although, however not to the same extent as coercive, traces of 
normative and mimetic isomorphism within the industry has been discovered. Normative with 
the extended human resource network through M&As and the specialized role of MSs, while 
mimetic patterns are found in the wholesaler's added value services.   
Altogether, this report can conclude that the pharmaceutical wholesale industry in Japan is 
showcasing patterns of isomorphism, just like Japanese pharmaceutical manufacturers do, as 
Slater et al. (2008) found out. However, with the nature of low margins for the wholesalers it 
is found how divergent forces are present as wholesalers try to differentiate themselves by 
finding unique added value services. This implies that under certain circumstances, like 
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Japan's health care issues which has led to the tougher climate for wholesalers, isomorphic 
behavior does not have to be clearly evident.          
6.3 Practical implications  
The results of this report are aimed to contribute to Lundbeck K.K. needs. Even though it is 
aimed towards a specific company, it can be of use for all actors in the pharmaceutical 
organizational field operating in Japan, especially other wholesalers. The report gives 
valuable information of how the pharmaceutical wholesalers are affected by different external 
factors which affect the way they work. With a deeper knowledge about the wholesale market 
that this report contributes with, actors in the industry receive knowledge on how, mainly the 
big four, wholesalers meet the difficulties on the market and what kind of added value they 
contribute with. With both specific interviews conducted with relevant people inside big 
wholesale groups, actors in the industry, and a lecturer, in combination with secondary 
sources where information have been processed, this report contributes both on an industry 
specific level and gives an overview of how the pharmaceutical wholesale industry is affected 
by external factors.    
6.4 Future research      
The governmental agency MHLW mention how they want provide top quality health care in 
Japan. Their actions create a tough climate for the wholesalers which have had to cut costs 
and thus cannot provide the highest quality in service. The society is facing a paradox where 
one part affects the other. An important characteristic for Japanese pharmaceutical 
wholesalers is that 98 percent of the drugs go through one of them. It is surprising how the 
government has not showed more support for the wholesalers, as they are the carrier of the 
Japanese people's survival. A research in the near future would therefore be of relevance to 
see if the conditions for the wholesalers have changed with Japan's changing demographics 
and the government's goal to reduce health care costs. If the wholesalers margins continue to 
decrease it would be of interest to see if the Japanese government would take any actions 
towards this in favor for wholesalers.  
Further, as seen by this report the industry researched about has shown patterns of 
isomorphism. Taking this theoretical approach to another market with a different national 
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condition than Japan would be of interest and then compare the markets to see if the 
underlying changes lie within the researched nation's domestic conditions.  
Finally, to make a better generalization of the industry, it would be necessary to do future 
research with more actors in the field to be able to conclude more certain how wholesalers in 
Japan's pharmaceutical market are being affected by external changes. With a changing 
industry, the factors found in this report might change in the future.   
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8. Appendix 
8.1 Interview questions 
What effects have M&As had on the wholesale business?  
What added value do you see wholesalers offer?   
How have MSs role evolved due to deregulations and reorganizations?   
How are the NHI Price Revision, the government’s generic drugs goal, and prescription vs. 
dispensing affecting wholesalers business?   
What does the increase in delivery spots mean for wholesalers?   
What implications is ICT having on wholesalers business?   
How does an extended business domain affect wholesalers?  
How are wholesalers affected by the anti-monopoly act?  
 
 
 
